{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-043809","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.812737+00:00","generated_at":"2026-05-24T06:30:03.799964+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aura Biosciences Q4/FY2024 results: net loss $86.9M, cash $151.1M, Phase 3 CoMpass actively enrolling","bullets":["Net loss $86.9M in FY2024 vs $76.4M in FY2023; R&D expenses $73.3M.","Cash $151.1M as of Dec 31, 2024; runway into 2H 2026.","Phase 3 CoMpass trial actively enrolling; >175 patients pre-screened globally since June 2024.","Phase 2 trial in choroidal metastases initiated; initial data expected 2025.","Phase 1 NMIBC data showed clinical complete responses; Tony Gibney appointed Senior Finance and Strategy Advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-043809","json":"https://secwatch.observer/filing/0000950170-25-043809.json","markdown":"https://secwatch.observer/filing/0000950170-25-043809.md","text":"https://secwatch.observer/filing/0000950170-25-043809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025043809/0000950170-25-043809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025043809/aura-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:30:03.799964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}